Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma
Clinical trial NCT02032810 · COMPLETED
Trial details
- NCT number
- NCT02032810
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-01-07
- Primary completion
- 2017-09-06
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.